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Inhibiting the RAS oncogenic protein has largely been through targeting the switch regions
that interact with signalling effector proteins. Here, we report designed ankyrin repeat pro-
teins (DARPins) macromolecules that specifically inhibit the KRAS isoform by binding to an
allosteric site encompassing the region around KRAS-specific residue histidine 95 at the helix
α3/loop 7/helix α4 interface. We show that these DARPins specifically inhibit KRAS/effector
interactions and the dependent downstream signalling pathways in cancer cells. Binding by
the DARPins at that region influences KRAS/effector interactions in different ways, including
KRAS nucleotide exchange and inhibiting KRAS dimerization at the plasma membrane. These
results highlight the importance of targeting the α3/loop 7/α4 interface, a previously
untargeted site in RAS, for specifically inhibiting KRAS function.
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Members of the RAS family of oncogenic proteins arefrequently mutated in human cancers. In particular,KRAS mutations are the most prominent ones, repre-
senting around 86% of all RAS mutations1. KRAS mutants are
major drivers of cancers, such as colorectal, lung or pancreatic
cancers1. Isolation of selective KRAS inhibitors that block its
function is therefore an important goal2. Nonetheless, selectively
targeting KRAS is challenging, as RAS isoforms are highly similar
in primary sequence with 82–90% amino acid sequence identity3.
Most current inhibitors target all RAS isoforms via their con-
served effector lobe (defined as amino acid 1–86) by inhibiting
RAS/effector interactions4–7 or RAS nucleotide exchange8,9. We
identified such pan-RAS inhibitors in a previous study with the
anti-RAS designed ankyrin repeat proteins (DARPins) K55 (RAS/
effector interactions inhibitor) and K27 (RAS nucleotide
exchange inhibitor)8. As an alternative, targeting RAS via its
allosteric lobe (amino acids 87–166)10 is a possible way to inhibit
its function in cells11–13. The α3–α4 and α4–α5 interface in the
allosteric lobe are potential dimerisation sites for RAS14–17 and
preventing KRAS dimerisation impairs the mitogen-activated
protein kinase (MAPK) signalling pathway18. Recent studies have
shown that dimerisation is a potential targetable feature of KRAS
function11–13. Notably, a monobody that targets both HRAS and
KRAS on the α4–α5 site, disrupts RAS dimerisation, blocks RAF
activation12 and inhibits tumour formation in vivo13. Never-
theless, none of these inhibitors are KRAS selective.
Specifically targeting directly mutant KRAS has been achieved
with small molecules covalently binding the G12C mutant
KRAS19–21. This approach targets the G12C mutation that
represents around 12% of KRAS mutations in cancers (Cosmic
database v86, https://cosmic-blog.sanger.ac.uk/), and is only
present in a subset of cancers, such as non-small cell lung can-
cers22. Therefore, alternative strategies are needed to inhibit the
most frequent mutations of KRAS accounting for 88% of KRAS
mutant cancers.
We report here the characterisation of two potent DARPins
that selectively bind KRAS on a site of the allosteric lobe,
encompassing histidine residue 95. The DARPin binding inhibits
KRAS nucleotide exchange and KRAS dimerisation, thus
impairing mutant KRAS–effector interactions and the down-
stream signalling pathways. These findings reveal a unique
strategy to selectively inhibit KRAS.
Results
Isolation of anti-KRAS-specific DARPins. We performed a
phage display selection of a diverse DARPin library8, followed by
immunoassays with KRASG12V to isolate hits. We have identified
two DARPins (designated K13 and K19) that bound to
KRASG12V. Biochemical analysis of the DARPins show K13 and
K19 interact with KRAS independently of the nucleotide-bound
state of the GTPase, and have Kds around 30 and 10 nM,
respectively (Supplementary Fig. 1a). The nucleotide and protein
sequences of DARPins K13 and K19 are shown in Supplementary
Fig. 1b, c and highlight a conserved amino acid sequence in the
repeat regions with only six amino acids difference.
The X-ray structure data of K13 and K19 in complex with
KRASG12V show these DARPins bind to the allosteric lobe of
KRAS, at the interface between helix α3/loop 7/helix α4 (Fig. 1a, b;
Supplementary Table 1). The crystal structures show that when
DARPins K13 or K19 bind to KRAS, a structural change appears
in the KRAS molecule on the effector lobe, especially on the switch
1 and 2 when compared with two unbound KRASG12V-GDP
structures (Supplementary Fig. 2a, b). However, the exact
conformation of the switch 1 loop in the K13- and K19-bound
states differ somewhat. This difference is most likely due to their
different crystal-packing environments (Supplementary Fig. 2c, d).
NMR chemical shift perturbation HSQC and hydrogen deuterium
exchange with mass spectrometry (HDX-MS) data support the
observed binding interface in solution of K19 in the allosteric lobe
(Fig. 2a–c and Supplementary Figs. 3–5) and control DARPin K27
in the effector lobe (previously shown to interact with the switch
regions of KRAS, NRAS and HRAS-GDP8) (Supplementary Figs.
4–6). After K19 binding to KRAS, a small but significant increase
in the dynamic mobility of the switch 2 loop is shown by the
increase in de-protection observed by HDX-MS (Supplementary
Figs. 3–4), and some small perturbations of the effector lobe
HSQC resonances are observed in a few residues in the switch 2
region (Fig. 2a–c). Our data suggest that the conformational
change observed by X-ray crystallography on the switch regions is
most likely due to the crystal-packing effect, because the switch
regions are flexible by nature.
DARPins K13 and K19 are KRAS selective binders. K13 and
K19 interact with the allosteric lobe where the amino acids
between the RAS isoforms are less conserved than the effector
a b
RAS (K13 bound) RAS (K13 bound)
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Fig. 1 DARPins K13 and K19 bind KRAS to a novel allosteric site. a X-ray crystal structures of KRASG12V-GDP-bound to DARPin K13 (PDB 6H46) and
KRASG12V-GDP-bound to DARPin K19 (PDB 6H47) with the indication of RAS switch regions, helix 3 (α3), helix 4 (α4) and loop 7 (L7) regions. b Expanded
view of the interaction between the DARPin K13 and KRAS around histidine residue 95 of KRAS
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lobe. Thus, we assessed whether K13 and K19 could bind to all
RAS family isoforms. While the switch region-binding DARPin
K27 binds to K, N and HRAS in cell-based bioluminescent
resonance energy transfer 2 (BRET2) assay23, K13 and K19 show
only strong binding with KRAS (Fig. 3a, b). In addition, K13 and
K19 interact equally with the dominant-negative KRASS17N, the
constitutively activated mutant KRASG12D and wild-type KRAS,
unlike K27, which does not contact the KRASS17N mutant
(Fig. 3a, b). Indeed, K13 and K19 bind KRAS away from the
switch regions, and are not affected by the S17N mutation
while K27 binding is expected to be affected as the flexibility of
the switch regions is modified on that mutant24. These selectivity
findings were further supported using a co-immunoprecipitation
assay with cells co-expressing 3xFLAG-tagged wild-type RAS and
GFP-tagged DARPin. KRAS, NRAS and HRAS proteins were
immunoprecipitated on beads, and the presence of DARPin–GFP
bound to RAS proteins was assessed. The DARPin K27 was
captured by all three RAS isoforms, but K13 and K19 were only
captured by KRAS, while the negative control DARPin E3.58 was
not co-immunoprecipitated by any RAS proteins (Fig. 3c).
K13 and K19 bind KRAS by interacting with the H95 of KRAS.
We evaluated which residue(s) are involved in this KRAS selec-
tivity of K13 and K19. Analysis of the amino acids engaged in the
interaction between the DARPins and KRAS, showed that K13
and K19 make extensive interactions with the histidine 95 and the
glutamic acid 107, which are residues only present in KRAS
(Supplementary Fig. 7a). Therefore, we introduced mutations on
the positions 95 and 107 of wild-type (WT) KRASWT substituting
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Fig. 2 HSQC NMR chemical shift changes in KRAS after DARPin K19 binding. a Comparison between 1H, 15N TROSY spectra for apo KRASG12V at 100 μM
(black) overlaid with K19-bound KRASG12V at 89 μM (green). DARPin concentrations were in slight excess. An expanded region is shown on the right.
b Amino acids undergoing chemical shifts upon DARPin K19 binding on KRASG12V-GDP are shown in blue, residues not experiencing shifts are shown in
turquoise in the KRASG12V sequence (unassigned residues are not highlighted). The P-loop is highlighted in yellow, the switch 1 in dark yellow and the
switch 2 in purple. c Ribbon representation of (b) with amino acids undergoing chemical shifts in blue and residues not experiencing shifts in turquoise in
the KRASG12V-GDP structure (PDB 4TQ9) after DARPin K19 binding (unassigned residues are in grey). L7: loop 7, α3: helix 3, α4: helix 4
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HIS95 with leucine or glutamine (found at residue 95 in NRAS
and HRAS, respectively) and substituting GLU107 with aspartic
acid (found at residue 107 in both NRAS and HRAS). While the
E107D mutation did not affect K13, K19 or K27 DARPins
binding with KRAS (Fig. 3d), H95Q and H95L mutations dras-
tically decrease K13 and K19 binding on KRASWT but do not
affect K27 binding as shown by BRET (Fig. 3d) or co-
immunoprecipitation (Supplementary Fig. 7b). Supplementary
Table 2 summarises the effects of RAS mutations on the binding
of the DARPins. Finally, we assessed the residues of the DARPins
important for binding to KRAS by mutating two tryptophans
found in the first repeat of both K13 and K19 to glycine residues
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Fig. 3 K13 and K19 are KRAS selective binders. a BRET donor saturation assay between KRASG12D or KRASS17N (donors) and the DARPins (acceptors).
b BRET donor saturation assay between KRASWT, NRASWT, NRASQ61H, HRASWT or HRASG12V (donors) and the DARPins (acceptors). c Co-
immunoprecipitation of 3xFLAG-KRASWT, −NRASWT and −HRASWT with the DARPin-GFP2 fusions in 10% foetal bovine serum. IP Immunoprecipitation,
WCE whole-cell extract. d BRET donor saturation assay between KRASWT, KRASH95Q, KRASH95L or KRASE107D (donors) and the DARPins (acceptors).
Note that most of the donor saturation curves with K27 as acceptor are overlapping in panels b and d. Each experiment was performed three times (a–d).
Error bars are mean ± SD of biological repeats. c Source data are provided as a Source Data file
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(Supplementary Fig. 1b, c) and analysing BRET interaction signal
with KRASG12D. These mutations induce a significant decrease of
K13 and K19 binding to KRAS (Supplementary Fig. 7c, d). We
conclude that the main driver for KRAS selectivity is the inter-
action between the H95 of KRAS with the W35 and W37 of the
DARPins K13 and K19.
DARPins K13 and K19 inhibit KRAS/effector interactions in
cells. We assessed whether K13 and K19 interfere with KRAS
function by inhibiting KRAS/effector interactions using the BRET
assay. The DARPins were fused on their C terminus to a mCherry
tag for monitoring their expression level (mCherry excitation and
emission spectra do not overlap with those of our BRET2 donor
or acceptor constructs)25,26. Unlike the negative control DARPin
E3.5, K13 and K19 impede KRASG12D to interact with all the
effector domains tested, including CRAF RBD (Fig. 4a; Supple-
mentary Fig. 8a). Moreover, K13 and K19 selectively inhibit
KRASG12D/full-length CRAFS257L (CRAFFL), but do not sig-
nificantly alter NRASQ61H/CRAFFL or HRASG12V/CRAFFL
interactions (Fig. 4b–d; Supplementary Fig. 8b), while K27
interferes with all three. Finally, K13 and K19 also induce a
selective inhibition of the RAF/MEK/ERK signalling pathway
mediated by KRASG12D/CRAFFL overexpression in
HEK293T cells (Supplementary Fig. 9a, b). These results suggest
that K13 and K19 are selective KRAS inhibitors.
K13 and K19 inhibit KRAS-dependent signalling in cancer
cells. We tested the inhibitory effect of the DARPins in the fol-
lowing cancer cell lines: HCT116 (a colorectal cancer cell line,
KRASG13D), HT1080 (a fibrosarcoma cell line, NRASQ61K), T24 (a
bladder carcinoma cell line, HRASG12V) and MCF-7 (a breast
adenocarcinoma cell line, RASWT). These were transiently trans-
fected 24 h with the DARPins, and both RAF/MEK/ERK and
PI3K/AKT pathways were assessed by western blot analysis. While
K27 inhibits the RAF/MEK/ERK pathway in the three RAS
mutant cell lines and the RASWT cancer cell line tested (consistent
with its binding to the switch regions), K13 and K19 only decrease
significantly the phosphorylation of MEK and ERK kinases in the
KRAS mutant HCT116 cell line, but not in either the NRAS or the
HRAS mutant cell lines or the RASWT cancer cell line (Fig. 5a, b).
K13 and K19 DARPins selectively inhibit the PI3K/AKT pathway
in the KRAS mutant HCT116 cell line, but not in the other cancer
cell lines, while K27 inhibits this pathway in HCT116 and MCF-7
cells (Fig. 5a, b). These data are consistent with the finding that the
PI3K/AKT pathway is only partly dependent on RAS, and can be
activated independently of RAS27,28. These results demonstrate
that K13 and K19 selectively inhibit endogenous mutant KRAS
function without affecting RASWT cancer cells.
K13 and K19 inhibit KRAS function by at least two mechan-
isms. While K13 and K19 bind to the allosteric lobe of KRAS and
interfere with effector interactions, it suggested new mechanism
(s) by which DARPins inhibit KRAS function. To this end, we
tested these DARPins in biochemical assays, where K13 and K19
were compared with the known RAS nucleotide exchange inhi-
bitor K27 and known RAS/CRAF RBD interaction inhibitor
K558. In vitro analyses show that DARPins K13 and K19 inhibit
the biochemically coupled KRAS assay based on the inhibition of
nucleotide exchange or KRAS–CRAF RBD interaction (Fig. 6a) as
does K27 but, unlike K55, K13 and K19 do not prevent KRAS/
CRAF RBD interaction in vitro (Fig. 6b) even though they do in
the cell-based BRET assay (Fig. 4a). Furthermore, these DARPins
lock down the GDP- and GTP-bound KRAS, thus preventing the
nucleotide exchange by SOS (Fig. 6c). Nonetheless, the binding of
the DARPins to KRAS is nucleotide independent (Fig. 3a; Sup-
plementary Fig. 1a), and the binding occurs on a surface remote
from the switch regions (Fig. 1). However, SOS not only contacts
RAS near the switch 1 and 2 regions but also makes additional
interactions with the residues 95–105 of the helix α329. These
contacts would cause a clash between K13 and SOScat for KRAS
binding (Fig. 6d) and indicate why K13 and K19 inhibit the
nucleotide exchange of KRAS.
In addition, we investigated whether the DARPins could
interfere with KRAS dimerisation, as it has been previously
described with a different allosteric inhibitor, the monobody
NS112. Indeed, the α3–α4 and α4–α5 regions are defined as the
potential dimer interfaces of KRAS14–17 and K13 and K19
interact with the α3–α4 site of KRAS (Supplementary Fig. 7a).
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Fig. 4 K13/K19 prevent KRAS/effector interactions in cells. a BRET competition assays between KRASG12D/effector domain interactions and the DARPins
used as competitors. The effector domains used were PI3Kα RBD, PI3Kγ RBD, CRAF RBD and RALGDS RAS-associating (RA) domain. b–d BRET
competition assays between CRAFFL/KRASG12D (b), NRASQ61H (c) and HRASG12V (d) interactions with the DARPins used as competitors. E3.5 is a
negative control, and DARPin K27 is a positive control. Statistical analyses in a–d were performed using a one-way ANOVA followed by Dunnett’s post-hoc
tests (***P < 0.001, ****P < 0.0001, ns not significant). Each experiment was performed three times (a–d). Error bars are mean ± SD of biological repeats.
a–d Source data are provided as a Source Data file
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Consequently, the binding of K13/K19 with KRAS is expected to
perturb its dimerisation. We tested this hypothesis by BRET
experiments involving the dimerisation of mutant K-, N- and
H-RAS. K13 and K19 essentially inhibit KRASG12D dimerisation,
while NRASQ61H and HRASG12V dimers formation is less
affected by the DARPins (Fig. 7a–c).
It has been previously reported that the CAAX motif of RAS is
mandatory for its dimerisation18. Therefore, we investigated RAS
dimerisation using KRASG12V deleted of its last 22 amino acids
(a KRASG12V166 mutant missing the whole hypervariable region,
HVR, including the CAAX motif) that should remove its ability to
form RAS dimers. First, we showed that KRASG12V166 was soluble
and expressed in the cytoplasm of cells (Supplementary Fig. 10a)
and was not able to form dimers in cells by BRET donor saturation
assays (Supplementary Fig. 10b). We then performed a BRET
competition assay with K13 and K19 against KRASG12V FL or
KRASG12V166 interaction with CRAF RBD showing that removal of
the HVR from KRASG12V only reduced K13/K19 inhibition of
KRASG12V/CRAF RBD interaction (Supplementary Fig. 10c). These
results show that RAS dimerisation in cells is not the only
mechanism of inhibition of KRAS by the DARPins, as these retain
the ability to inhibit KRASG12V166/CRAF RBD interaction.
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Fig. 5 K13/K19 inhibitory potency in cells. a Western blot analyses of the activation state of the RAF/MEK/ERK and PI3K/AKT pathways in cancer cell
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Discussion
We reported here KRAS-selective inhibitors that bind to a pre-
viously untargeted site on the allosteric lobe of KRAS and prevent
KRAS-mediated signalling. We have studied two DARPins,
sharing a conserved amino acid sequence, that bind on the same
interface of KRAS, the helix α3/loop 7/helix α4 region. The
tryptophan residues 35 and 37 of K13 and K19 contact the his-
tidine 95 of KRAS, which is a residue only found in KRAS thereby
conveying their KRAS selectivity. These DARPins differ sig-
nificantly from our previously isolated anti-RAS DARPins that
included a pan-RAS-GTP binder (K55) that inhibits RAS/effector
interactions and a pan-RAS-GDP binder (K27) that prevents RAS
nucleotide exchange, both DARPins targeting the switch regions
of RAS. We have now characterised K13/K19 DARPins that
specifically contact KRAS (GTP and GDP bound) on an allosteric
site remote from the switch regions and impede KRAS nucleotide
exchange and dimerisation.
Even though K13/K19 bind to both mutant and WT KRAS,
they only prevent RAS-dependent signalling in KRAS mutant
cancer cells (HCT116) and do not affect RAS signalling in
RASWT cancer cells (MCF-7) (Fig. 5). In a previous study, an
antisense oligonucleotide (AZD4785) was described that selec-
tively targets KRAS mRNA30, but both wild-type and mutant
mRNAs. AZD4785 downregulates both WT and mutant KRAS
protein, but only inhibits the downstream MAPK and PI3K sig-
nalling pathways of mutant KRAS expressing cells and not of
KRASWT expressing cancer cells30. Therefore, our data also
suggest that inhibition of both WT and mutant KRAS do not
affect the RAS downstream signalling pathways of RASWT cancer
cells. This effect could be explained by compensatory and/or
redundancy mechanisms of the other RAS isoforms31.
Although the crystal structures of K13 and K19 bound to
KRAS show substantial conformational change on both switch
regions, the NMR HSQC and HDX-MS only show a small con-
formational change on the switch 2 region of KRAS upon the
DARPins binding (Fig. 2 and Supplementary Figs. 3–6). In
addition, K13/K19 do not prevent the interaction KRASG12V/
CRAF RBD in vitro (Fig. 6b), indicating that the conformational
change of the switch 2 is not the main driver of KRAS function
inhibition in cells. The mechanism by which K13 and K19 inhibit
KRAS function is complex. KRAS dimerisation occurs through
the α3–α4 and/or α4–α5 interfaces that are dimerisation inter-
faces of KRAS14–17. However, only the α4–α5 has been func-
tionally tested in cells11–13. We now show that targeting α3–α4
interface also leads to KRAS function inhibition. The mechanism
underlying this inhibition could rely on inhibition of RAF acti-
vation as described with a monobody12. The DARPin binding
may also promote a certain degree of membrane occlusion of the
effector-binding region of KRAS and impede the binding of
effectors on the switch regions32. Nevertheless, because the GEF
SOS contacts the α3 region of RAS29 (as well as switch 1 and 2),
K13 and K19 presumably also impede KRAS nucleotide exchange
by engaging the α3–α4 site. Therefore, it adds another level of
complexity in the interpretation of the mechanisms responsible
for KRAS inhibition. We conclude that K13/K19 can affect KRAS
function by at least two different mechanisms, including
nucleotide exchange and RAS dimerisation inhibition.
None of the mechanisms above would explain why DARPins
K13 and K19 disrupt the binding of K27 to KRASWT in a BRET
competition assay in cells (Supplementary Fig. 11a). This inter-
action should not rely on RAS dimerisation, since K27 interacts
predominantly on the switch 1 of KRAS–GDP and no steric clash
appears visible between K27 and K13 or K19 (Supplementary
Fig. 11b, c). Therefore, the mechanism of inhibition of KRAS by
K13 and K19 seems more complex than only the prevention of
nucleotide exchange and KRAS dimerisation. While K27 only
binds KRAS–GDP, K13/K19 also interact and lock down GTP-
bound KRAS (Fig. 6c; Supplementary Fig. 1a). Hence, K13/K19
could inhibit the GTPase-activating proteins (GAP) binding on
KRAS. The superimposition of the structures of two GAP pro-
teins (p120 RAS GAP, PDB 1WQ1 and NF1, PDB 1NF1) with the
structures of KRASG12V-GDP/K13 (Supplementary Fig. 12a, b)
and KRASG12V-GDP/K19 (Supplementary Fig. 12c, d) shows that
the amino terminal end of these DARPins would overlap with the
bound GAP proteins, suggesting that K13/K19 may be GAP
inhibitors. Even though a putative GAP inhibitory mechanism
could explain the inhibition of KRASWT/K27 interaction by K13/
K19, it is not the mechanism that prevails in either mutant KRAS
or KRASWT cancer cells. Indeed, RAS signalling is decreased in
HCT116 cells (bearing both mutant andWT KRAS alleles), and is
not increased in MCF-7 cells (homozygous for KRASWT) when
K13/K19 are expressed (Fig. 5). Nevertheless, HT1080 cells
(bearing NRASQ61K and KRASWT alleles) expressing K19 present
an increased level of pERK and pMEK signals (Fig. 5). This result
could be assigned to the inhibition of the GAP binding on
KRASWT by K19. However, this effect is not observed in T24 cells
(bearing HRASG12V and KRASWT alleles), suggesting this increase
of signalling might be cell line dependent. Therefore, the GAP
inhibitory effect on RAS downstream signalling could be balanced
by the dimerisation inhibition of KRASWT and/or by compen-
satory mechanisms involving for instance the two other RAS
isoforms31 and explaining why RAS signalling is not always
affected in KRASWT cancer cells, such as MCF-7.
The therapeutic use of these inhibitors with an intracellular
protein such as KRAS is currently limited, but this work has
identified an allosteric site on KRAS and the different inhibitory
mechanisms involved in targeting this interface. Hence, the α3/loop
7/α4 region could be targeted for inhibition via alternative
approaches. In future studies, the DARPins K13 and K19 could
be used as surrogates to select small molecules targeting the α3/loop
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7/α4 allosteric interface, especially around the KRAS selective resi-
due H95. The surrogate method has been successfully used pre-
viously to isolate RAS-binding compounds using an anti-RAS
intracellular single-domain antibody fragment7. Furthermore, an in
silico study showed a potential small molecule-binding site on that
interface33. This would be a promising way to isolate KRAS selec-
tive small inhibitors for the treatment of KRAS mutant cancers.
Methods
Isolation of DARPins K13 and K19. DARPins were isolated from a phage display
library34 by panning selections on biotinylated KRASG12V (1–166) pre-bound to
streptavidin magnetic beads, as previously described8. DARPin K19 was isolated
from a first round phage display output that was further selected against KRASG12V
(1–166) by ribosome display and error prone mutagenesis, using methods
described by Groves et al.35 To convert a DARPin phage display library into a
format compatible with ribosome display, primer DARPin-RD1 (5′- AGACCACA
ACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATAT
CCATGGCCGATCTGGGAAA-3′) was used in place of primer SDCAT-DP4735.
For characterisation, DARPins were sub-cloned to the pET16b vector and
expressed cytoplasmically in BL21 (DE3) Escherichia coli (New England Biolabs). A
list of the primers used in this study is shown in Supplementary Table 3. Following
lysis in BugBuster plus Benzonase (EMD Millipore), DARPins were purified to
homogeneity using nickel-chelate chromatography, followed by size exclusion
chromatography to provide a monomeric protein in PBS (pH 6.5).
KRAS expression and purification. The human KRAS gene sequence (residues
1–166, Isoform 2B, P01116-2) containing the G12V substitution was cloned into a
pET28b vector with an N-terminal His6 tag. KRASG12V was expressed in BL21
(DE3) Escherichia coli (New England Biolabs) and cell pellets resuspended in
50 mM HEPES (pH 7.4), 100 mM NaCl, 20 mM Imidazole, 2 mM TCEP and 2 mM
MgCl2. Following sonication, the sample was centrifuged at 20,000 rpm and pro-
teins purified from the supernatant by Ni-NTA chromatography on a 5 -mL
HisTrap HP column (GE Life Sciences, cat # 17-5248-02). Following elution in
50 mM HEPES (pH 7.4), 500 mM NaCl, 400 mM Imidazole, 2 mM TCEP and
2mM MgCl2, samples were further purified by size exclusion chromatography on a
Superdex 75 column. Final buffer composition was 50 mM HEPES (pH 7.4),
100 mM NaCl, 2 mM MgSO4. KRASG12V was biotinylated via an Avi tag using
BirA enzyme and then exchanged with either GDP or GTPγS, catalysed by SOS
(Son of Sevenless). The GTPγS in the KRAS GTPγS had a tendency to be
hydrolysed to GDP on storage, so the levels were determined by electrospray mass
spectroscopy.
X-ray structure. DARPins K13 and K19 were mixed with KRASG12V-GDP in
equimolar ratio with a final concentration of 16 mg.mL−1 and incubated on ice for
30 min prior to crystallisation screening at 277 and 293 K. Hits were observed in
several conditions. Both K13 and K19 complexes gave bipyramidal crystals in
0.5–1.0 M lithium sulphate, 0.5–1.0 M ammonium sulphate, 100 mM tri-sodium
citrate pH 5.5. A cryoprotectant solution of 2M lithium sulphate could be used for
crystals of both complexes.
The diffraction data were collected at 100 K temperature at the Diamond Light
Source, UK on beamlines I04-1 and I03 at 0.920 and 0.976 Å wavelength,
respectively. XDS, pointless and scala were used to process the data. Model building
and subsequent refinement were carried out with Coot and Refmac. There are no
Ramachandran outliers in either structures and over 98% are in the most favoured
region. Coordinates and structure factors were deposited in the PDB with accession
codes 6H46 and 6H47. Data collection and refinement statistics are summarised in
Supplementary Table 1.
NMR spectroscopy. Protein was expressed in BL21-Gold cells grown in M9 media
supplemented with 5 g.L−1 Celtone N powder and containing 50 μg.mL−1 kana-
mycin and 15 μg.mL−1 tetracycline. Purification was performed as described above.
Protein was dialysed overnight into NMR buffer (50 mM HEPES pH 7.4, 50 mM
NaCl, 2 mM MgCl2, 2 mM TCEP, 0.1 mM EDTA, 0.02% NaN3)36. All NMR
spectra were collected at 298 K on a Bruker 800MHz, Avance III spectrometer,
equipped with a 5 -mm TCI Cryoprobe with z-axis gradients using standard
experiments and parameters from Bruker library. Uniformly 15-N-labelled
KRASG12V was used at a concentration of 100 μM with concentrations of added
non-labelled DARPins as indicated. NMR samples were prepared in HEPES-based
buffer at pH 7.4 supplemented with 5% D2O. All spectra were processed in Topspin
3.1. Binding was monitored by 1H-15N 2D TROSY (transverse relaxation opti-
mised spectroscopy) spectra of the protein acquired with (F2 × F1) 2048 × 160
complex pairs (in Echo-Antiecho mode), 12019 × 2757 Hz sweep width and 85.2 ×
29.0 ms acquisition times. Assignments were mapped from deposited assignments
of KRASWT BMRB ID: 18529 and HRASG12V BMRB ID: 25730.
HDX mass spectrometry. Protein samples for HDX-MS were prepared in 20 mM
HEPES–Na pH 7.4, 100 mM NaCl, 5 mM MgCl2, 1 mM TCEP at final protein
concentrations of 10 μM GDP-loaded KRASG12V and 20 μM DARPin, and kept at
4 °C, unless otherwise stated. The deuterium exchange reactions were performed
using a LEAP PAL RTC system (LEAP Technologies) and all conditions were
performed in triplicate. Peptides were identified that covered 98.8% of the protein
sequence; considering the rapid back-exchange of the two N-terminal residues, this
reduces to 91.7%.
Deuterium exchange reactions were initiated by diluting the protein solutions 1:20
in 20mM HEPES–Na pH 7.4, 100mM NaCl, 5mM MgCl2, 1 mM TCEP prepared in
D2O (99.9% atom D, Sigma Aldrich), and incubating at 20 °C for 15 s, 60 s, 300 s,
900 s, 1800 s and 3600 s. Undeuterated controls were prepared by performing the
same dilution but in buffer prepared in H2O. The labelling reactions were quenched
by transferring 50 μL of the reaction mixture to 50 μL of pre-chilled quench solution
(3.0M urea, 1.6% (v/v) formic acid in water; 2 °C). Quenched samples were directly
injected onto an Enzymate BEH immobilised pepsin column (2.1 × 300mm, 3mm;
Waters) at 100 μL.min−1 at 20 °C for 3min at 10,000 psi. Peptic peptides were
trapped and desalted on an Acquity BEH C18 VanGuard pre-column (130 Å, 2.1 ×
5mm, 1.7 μm; Waters) kept at 0.1 °C. The trapped peptides were eluted using a 9 -
min gradient of 5–35% acetonitrile in 0.1% (v/v) formic acid at 40 μL.min−1 on an
Acquity UPLC BEH C18 column (130 Å, 1.7 μm, 100mm× 1mm; Waters) at 0.1 °C.
Peptides were detected on a SYNAPT G2-Si HDMS mass spectrometer (Waters)
acquiring over an m/z range of 50–2000 with an electrospray source and lock mass
calibration (Leucine Enkephalin, 200 pg.μL−1; Waters). The mass spectrometer was
operated at a source temperature of 80 °C and a spray voltage of 2.5 kV. Spectra were
collected in positive ion resolution mode.
Peptide identification was performed in Protein Lynx Global Server (Waters)
using MSE data collected for the triplicate undeuterated control samples. The resultant
peptide lists were imported into DynamX (Waters) where peptides were filtered:
minimum intensity of 5000, minimum of 0.3 products per amino acid, a maximum
MH+ error of 5 ppm, and found in all of the undeuterated data sets. The automatic
peptide assignment in DynamX was performed using the standard parameters, but all
peptides were manually checked for the charge-state assignment, overlapping peptides
and retention time. The data were not corrected for back exchange, so are relative
rather than absolute deuterium uptake values. The first two residues of each peptide
were excluded from analyses due to rapid back exchange. Significant differences were
determined by performing a Student’s t test using the pooled standard deviation or
peptide standard deviation, whichever was the greater. The p-values were adjusted for
false discovery using the Benjamini–Hochberg procedure. Differences with p < 0.05
were considered significant.
Peptide-level differences in deuterium uptake are calculated according to the
Eq. (1):
pepstatei ¼ uptakestatei  uptakeapoi ð1Þ
pepistate: Difference in deuterium uptake for peptide i in state of interest
uptakeistate: Deuterium uptake for peptide i in state of interest
uptakeiapo: Deuterium uptake for peptide i apo state
The mean residue-level differences were calculated using the Eq. (2):
resj ¼
1
N
XN
i¼1
pepi
amidei
ð2Þ
resj: mean difference for residue j
N: number of peptides containing residue j
pepi: deuterium uptake difference for peptide i that contains residue j
amidei: number of exchangeable residues within peptide i
KRAS biochemical coupled assay and KRAS/CRAF RBD assay. The KRAS
biochemical coupled assay was performed as previously described8. Briefly, bioti-
nylated KRASG12V was pre-incubated with streptavidin–Europium chelate to form
a complex, and in a separate reaction, CRAF RBD-GST (glutathione-S-transferase)
was pre-incubated with anti-GST-XL665 to form a second complex. Test samples
were incubated with the streptavidin:KRAS complex for 15 min before addition of
GTPγS and SOS (to initiate nucleotide exchange) and the CRAF RBD:anti-GST
complex. Final concentrations added were 2 nM biotinylated KRAS; 37.5 ng.mL−1
streptavidin–Europium; 12 nM CRAF RBD-GST; 2 mg.mL−1 anti-RAF GST
XL665; 4 mM GTPγS and 2 mM SOS. In addition, the buffer for the CRAF RBD:
anti-GST complex contained 0.1 mg.mL−1 BSA and 0.1 M potassium fluoride.
After 1 h incubation, fluorescent resonance energy transfer (FRET) was measured
on an Envision plate reader at emission wavelengths 620 and 665 nm. The ratio of
these values was fitted using non-linear regression in the application Prism
(GraphPad Software). An assay to measure only the inhibition of KRAS/CRAF
RBD was like the coupled assay above, with the exception that test samples were
added after the completion of the nucleotide exchange step.
MANT nucleotide exchange and release assays. Exchange of GDP with fluor-
escent MANT-dGDP or fluorescent MANT-GTP on KRAS was studied in an assay
previously described8. DARPins were tested for inhibition of nucleotide exchange by
incubating at 10 μM with 500 nM KRASG12V, 1mM SOS and 500 nM MANT-dGDP
or MANT-GTP (Biolog). Exchange was measured over time by the increase in
fluorescence of MANT-dGDP or MANT-GTP upon binding to KRAS and detected
using an Envision plate reader (PerkinElmer) using 340 nm/450 nm excitation/
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emission filters. The data were captured at times from zero to 60min. For nucleotide
release assays, DARPins were added after equilibration of MANT nucleotides.
DARPin Kd measurements. ForteBio Octet Red384 was used to determine the
binding kinetics of DARPins to KRAS. Concentrations of DARPin K19 from
15,000 nM to 6.2 nM or DARPin K13 from 3000 nM to 12.4 nM were added to
sensors pre-loaded with biotinylated KRAS (1–166; wild-type; GDP or GTPγS),
associated for 300 s and dissociated for 600 s by washing in buffer. For each sample,
a reference well was included only containing buffer. The data were analysed using
ForteBio data analysis. Reference wells were subtracted from sample wells, and 1:1
local fitting model was used to fit curves to sensorgrams and determine kon, koff and
Kd values. The experiments were carried out in kinetic buffer from ForteBio.
Cell culture. HEK293T human embryonic kidney cells, HCT116 cells, HT1080 and
MCF-7 cells were grown in the DMEM medium (Life Technologies), and T24 cells
in the RPMI medium (Life Technologies). All cell lines were supplemented with
10% FBS (Sigma) and 1% penicillin/streptomycin (Life Technologies) and MCF-7
cells were also supplemented with 10 μg.mL−1 insulin (Sigma). Cells were grown at
37 °C with 5% CO2. The specific RAS mutations in the tumour cell lines were
confirmed using genomic PCR, cloning the PCR products and DNA sequencing.
Genotyping of RAS mutant cell lines. RNA was extracted from 5 × 106 HCT116,
HT1080, T24, and MCF-7 cells using the RNeasy Plus Mini Kit (Qiagen) according
to the manufacturer’s instructions. cDNA was synthesised from 2 μg of RNA using
SuperScript II Reverse Transcriptase (Invitrogen). Primers were designed to
amplify KRAS, NRAS and HRAS DNA, and incorporate HindIII and BamHI
restriction sites for sub-cloning:
KRAS_F: 5′-TAAGCAAAGCTTATGACTGAATATAAACTTGTGGTAG-3′
KRAS_R: 3′-GAAAATTAAAAAATGCATTATAATGTAAGGATCCTAAGCA-5′
NRAS_F: 5′-TAAGCAAAGCTTATGACTGAGTACAAACTGGTGGTGG-3′
NRAS_R: 3′-GGATTGCCATGTGTGGTGATGTAAGGATCCTAAGCA-5′
HRAS_F: 5′-TAAGCAAAGCTTATGACGGAATATAAGCTGGTGGTG-3′
HRAS_R: 3′-GCAAGTGTGTGCTCTCCTGAGGATCCTAAGCA-5′
DNA was amplified using Phusion High-Fidelity DNA Polymerase (New England
Biolabs) and, following digestion with HindIII and BamHI, the DNA was cloned into
pBlueScript II SK (+) (Stratagene). Plasmid DNA was prepared from individual
DH5a transformants using a QIAprep Spin Miniprep Kit (QIAGEN). KRAS, NRAS
and HRAS mutations were verified by Sanger sequencing (Source Bioscience) of at
least six clones from each cell line. The RAS mutations in the cell lines were confirmed
as KRASG13D (heterozygous) in HCT116, NRASQ61K (heterozygous) in HT1080,
HRASG12V (homozygous) in T24 cells and RASWT in MCF-7 cells.
Cells transfection. HEK293T cells were transfected with Lipofectamine 2000
(Thermo-Fisher, see the BRET2 section). HCT116, HT1080 and MCF-7 were
seeded in six-well plates (670,000; 300,000; 250,000 cells per well, respectively).
Cells were transfected 24 h later with 2.5 μg of pEF-DARPin-mCherry plasmid,
5 μL (HT1080 cells) or 8.75 μL (HCT116) or 6.25 μL (MCF-7) of Lipofectamine
LTX and 2.5 μL of PLUSTM Reagent (Thermo-Fisher) for another 24 h before
western blot analysis. T24 cells were transfected with the Neon transfection system
(Thermo-Fisher) following the manufacturer instructions. HCT116, HT1080 and
T24 were transfected in duplicate for each condition (two wells per condition).
Cells were pulled together before cell lysis (see the Western blot analysis section).
Molecular cloning. The following full-length KRAS constructs have been pro-
duced elsewhere: KRASS17N and KRASWT, all with carboxy terminal CAAX23.
KRASH95Q, KRASH95L and KRASE107D were produced by PCR site-directed
mutagenesis using pEF-RLuc8-KRASWT as a template23. The truncated
KRASG12V166 (missing the 22 last carboxy-terminal amino acids corresponding to
KRAS hypervariable region) was amplified by PCR using pEF-RLuc8-KRASG12V-
CAAX as a template and cloned between NotI/XbaI of the pEF-RLuc8-MCS and
pEF-GFP2-MCS. Wild-type NRAS and HRAS were obtained by PCR site-directed
mutagenesis using pEF-RLuc8-NRASQ61H and HRASG12V, respectively, as tem-
plates23. All RAS cDNAs (KRAS mutants, KRASWT, NRASQ61H and HRASG12V-
CAAX) were cloned between NotI/XbaI of the pEF-RLuc8-MCS, pEF-GFP2-MCS
and pEF-3xFLAG-MCS plasmids.
CRAF RBD (1–149), PI3Kα RBD (161–315), PI3Kγ RBD (190–315), RALGDS
RA (788–884) and full-length CRAFS257L cloning into pEF-GFP2-MCS or pEF-
MCS-GFP2 was described elsewhere23. DARPins were cloned between NcoI/XhoI
of the pEF-MCS-GFP2 plasmid and between NcoI/XhoI of the pEF-MCS-mCherry
plasmid. A list of the primers used in this study is shown in Supplementary Table 3.
BRET2 titration curves and competition assays. For all BRET experiments
(titration curves and competition assays), 650,000 HEK293T were seeded in each well
of a six-well plates. After 24 h at 37 °C, cells were transfected with a total of 1.6 μg of
DNA mix, containing the donor (RLuc8 plasmid)+ acceptor (GFP2 plasmid) ±
competitor (DARPin-mCherry plasmid), using Lipofectamine 2000 transfection
reagent (Thermo-Fisher). Cells were detached 24 h later, washed with PBS and seeded
in a white 96-well plate (clear bottom, PerkinElmer) in OptiMEM no-phenol red
medium complemented with 4% FBS. Cells were incubated for an additional 20–24 h
at 37 °C before the BRET assay reading. A step-by-step protocol is described
elsewhere37.
BRET2 measurements. BRET2 signal was determined immediately after addition
of coelenterazine 400a substrate (10 μM final) to cells (Cayman Chemicals), using
an Envision instrument (2103 Multilabel Reader, PerkinElmer) with the BRET2
Dual Emission optical module (515–30 and 410–80 nm; PerkinElmer). The total
GFP2 fluorescence was detected with excitation and emission peaks set at 405 and
515 nm, respectively. The total mCherry fluorescence was detected with excitation
and emission peaks set at 530 and 615 nm, respectively. The total RLuc8 lumi-
nescence was measured with the luminescence 400–700 nm-wavelength filter.
The BRET signal or BRET ratio corresponds to the light emitted by the GFP2
acceptor constructs (515–30 nm) upon addition of coelenterazine 400a divided by
the light emitted by the RLuc8 donor constructs (410–80 nm). The background
signal is subtracted from that BRET ratio using the donor-only negative control,
where only the RLuc8 plasmid is transfected into the cells. The normalised BRET
ratio is the BRET ratio normalised to a negative control (DARPin control) during a
competition assay. The total GFP2, mCherry and RLuc8 signals were used to
control the protein expression level from each plasmid.
Immunoprecipitation assay. HEK293T cells were transfected 48 h in duplicate
(two wells per condition) with pEF-3xFLAG-RAS and pEF-DARPins-GFP2 plas-
mids. Cells were washed once with PBS and lysed in the immunoprecipitation
buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.4, 10 mM MgCl2, 10% glycerol and
0.5% Triton) supplemented with protease inhibitors (Sigma) and phosphatase
inhibitors (Thermo-Fisher) for 20 min. Lysates were centrifuged for 15 min, and
the supernatant incubated with protein G magnetic beads (Life Technologies) and
anti-FLAG antibody (Sigma). The complexes were incubated 4 h at 4 °C on a wheel.
Beads were washed five times with the IP buffer, the bound proteins were eluted
with 1× loading buffer and resolved on 12.5% SDS-PAGE.
Western blot analysis. Cells were washed once with PBS and lysed in SDS-Tris
buffer (1% SDS, 10 mM Tris-HCl pH 7.4) supplemented with protease inhibitors
(Sigma) and phosphatase inhibitors (Thermo-Fisher). Cell lysates were sonicated
with a Branson Sonifier, and the protein concentrations determined by using the
Pierce BCA protein assay kit (Thermo-Fisher). Equal amounts of protein were
resolved on 10 or 15% SDS-PAGE and subsequently transferred onto a PVDF
membrane (GE). The membrane was blocked either with 10% non-fat milk (Sigma)
or 10% BSA (Sigma) in TBS-0.1% Tween20 and incubated overnight with primary
antibody at 4 °C. After washing, the membrane was incubated with HRP-
conjugated secondary antibody for 1 h at room temperature (RT, 25 °C). The
membrane was washed with TBS-0.1% Tween and developed using Pierce ECL
Western Blotting Substrate (Thermo-Fisher) and CL-XPosure films (Thermo-
Fisher). Primary antibodies include anti-phospho-p44/22 MAPK (ERK1/2)
(1/3000, CST, Cat#9101 S), anti-p44/42 MAPK (total ERK1/2) (1/1000, CST,
Cat#9102 S), anti-phospho-MEK1/2 (1/1500, CST, Cat#9154 S), anti-MEK1/2
(1/500, CST, Cat#4694 S), anti-phospho-AKT S473 (1/1000, CST, Cat#4058 S),
anti-phospho-AKT T308 (1/1000, CST, Cat#4056 S), anti-AKT (1/1000, CST,
Cat#9272 S), anti-pan-RAS (1/200, Millipore, Cat#OP40), anti-GFP (1/500, Santa
Cruz Biotechnologies, Cat#sc-9996), anti-DsRed (1/200, Santa Cruz Biotechnolo-
gies, Cat#sc-33353), anti-FLAG (1/2000, Sigma, Cat#F3165), anti-β-actin (1/2500,
Sigma, Cat#A1978) and anti-α-tubulin (1/2000, Abcam, Cat#ab4074). Secondary
antibodies include anti-mouse IgG HRP-linked (CST), anti-rabbit IgG HRP-linked
(CST) and anti-goat IgG HRP-linked (Santa Cruz Biotechnologies).
Confocal microscopy. HEK293T cells were seeded on coverslips and transfected
24 h with pEF-GFP2-KRASG12V166 construct. Coverslips were washed in PBS, fixed
10 min in 4% paraformaldehyde and washed twice in PBS. Then the coverslips
were mounted with DAPI Fluoromount-G overnight. Slides were analysed using a
Zeiss 880 Inverted Confocal Microscope with a ×63 objective. Confocal images
were analysed with ImageJ software.
Quantification and statistical analysis. The quantifications were performed
using ImageJ or Prism 7.0c (GraphPad Software), BRET titration curves and sta-
tistical analysis were performed using Prism 7.0c (GraphPad Software). The data
are typically presented as mean ± SD or SEM as specified in the figure legends.
Statistical analyses were performed with a one-way ANOVA followed by Dunnett’s
post hoc tests, unless otherwise indicated in the figure legends. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Structure files and coordinates have been deposited to PDB under these accession
numbers: 6H46 and 6H47. All relevant data are within the paper and its Supplementary
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Information file and the Source data file. The source data underlying Figs. 3c, 4a–d, 5a, b,
7a–c and Supplementary Figs. 7b, 9a, b, 10c and 11a are provided as a Source Data file.
Additional data supporting the conclusions are available from the corresponding author
on reasonable request.
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